Summary CV


M.B.B.S (Honours II Division I), University of NSW1978
F.R.A.C.S. Part I 1980, F.R.A.C.S. (Urology) Part 2 1988
V.Q.E 1980


Professor Stricker was awarded Australia’s 2nd highest award, the Officer of the Order of Australia  (AO) on the Australia Day 2015 Honours list for “Distinguished service to medicine and medical research, as a leading urologist, a robotic surgery pioneer, a teacher and mentor, and as an advocate for prostate cancer awareness “.

Selected Current Appointments

  • Chair Department of Urology, St Vincent’s Private Hospital and Clinic 2003 to date.
  • Director of the St Vincent’s Prostate Cancer Centre 2004 to date.
  • Clinical Director of Prostate Cancer at The Kinghorn Cancer Centre 2013 to date.
  • Clinical Associate Professor UNSW Medical School 2003 to date
  • Clinical Associate Professor Sydney Medical School, University of Sydney 2013 to date
  • Clinical Professor, School of Health Sciences, University of Tasmania, 2013 to date
  • Clinical Director – Australian Prostate Cancer Research Centre – NSW node 2013 to date
  • Conjoint Professor, School of Medicine, University of Western Sydney
  • Chairman, St Vincent’s Multidisciplinary Oncolcogy Team

Professor Phillip Stricker is an Urologist and one of the leading experts in the treatment of prostate cancer in Australia. He is Chairman of the Department of Urology at St Vincent’s Campus, the Director of the St Vincent’s Prostate Cancer Centre, Clinical Director of the Australian Prostate Cancer Research Centre – NSW and was an inaugural Director of the Prostate Cancer Foundation of Australia. He was the first person in Australia to specialise exclusively in the care of men with prostate cancer. In February 2006 he commenced the first robotic program in NSW at St Vincent’s Hospital. Since then he has performed over 2000 robotic prostate cancer cases, being the most in NSW and being only one of three robotic surgeons to achieve that in Australasia. He continues to perform open surgery and currently has performed in excess of 4500 open prostate cancer surgery cases being the most in Australasia. In non-surgical treatments he was one of the first to use low dose rate and high dose rate brachytherapy in Australasia and has now performed over 1,000 high dose rate and over 1000 low dose rate brachytherapies. He was one of the first to use active surveillance with one of the largest cohorts in the world ( >1000 patients).

Professor Stricker also has a long clinical and research track record of treating Benign Prostatic Hypertrophy including all the medications, laser surgery (being the first to perform greenlight laser in Australia), Urolift treatment and TURP.

His area of research currently focuses on the quality of life in patients after treatments ,improving surgical techniques , new techniques in robotic prostate surgery , introducing new treatments that are less invasive and with less side effects and investigating multiparametric magnetic resonance imagining alone and with combidex as an aid to biopsy, as a diagnostic tool and to assess the extent and aggressiveness of prostate cancer and to guide therapies . The use of Prostate Specific Membrane Antigen (PSMA) PET scans for the detection and evaluation of prostate cancer is a new research area of interest for Prof Stricker. In 2013, he was appointed the Clinical Director of the Australian Prostate Cancer Research Centre – NSW, which is funded by the Australian Federal Government. This Centre coordinates prostate cancer research across the St Vincent’s Campus, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Royal Prince Alfred Hospital/The Chris O’Brien Lifehouse and Royal North Shore Hospital. It is also in collaboration with researchers in Victoria, Queensland, South Australia and Western Australia. His international collaborative partnerships include the Memorial Sloan-Kettering Centre, New York, Cornell University, New York, Case Western Reserve University, Ohio, the Robotic Institute, Florida, Beth Israel Medical Center, New York and the University College Hospital, London. Together with the Garvan Institute of Medical Research, he has established a prostate cancer repository, which has collected clinical data and prostate cancer tissues samples for over 13,000 men one of the largest in the world. This has become a valuable resource for researchers who not only want to discover the molecular causes of prostate cancer but also the outcomes of diagnosis, treatment and prevention.

Translation – Current Selected Achievements

Active Surveillance:
Greater than 1000 cases on active surveillance since 1992. The largest series in Australia. Structured program of follow-up with PSA, transperineal biopsies of the prostate and MRI scans.

Open and Robotic Radical Prostatectomy:
Achieved international standard outcomes with <10% positive margins, up to 92% potency recovery and <2% long-term incontinence. These results have been presented and published in state, national and international meetings and journals.

Transperineal Biopsy
First described this technique in 1995, published and presented  extensively on it’s accuracy, safety and technique, has performed over 7,000 cases,and recently wrote the chapter by invitation in Hinman’s Textbook of Urology

MRI & PET Scanning
one of the pioneers of MRI prostate cancer imaging and PSMA Pet Scanning and has extensively presented and published on it’s role in detection, targeted biopsy ( including MR/US Fusion techniques), staging and monitoring and planning therapy.

Focal Therapy
One of the pioneers of focal therapy using IRE (Nanoknife). He currently has extensive experience and has performed over 600 cases of Focal IRE since 2013. Published data on the largest prospective focal Nanoknife therapy cohort in the world in European Oncology Urology.

Current Major Grants

  1. 2019 – 2023: Cancer Institute of NSW Programme Grant. $4million
  2. 2021 – 2022 St. Vincent’s Clinic Foundation Grant. Prospective cross-sectional multi-centre study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low or intermediate-risk prostate cancer (PIAS Trial). Stricker P and Thompson J $25,000
  3. 2021 – 2022 Ramaciotti Health Investment Grants. Prospective cross-sectional multi-centre study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low- or intermediate-risk prostate cancer (PIAS Trial). Stricker P and Thompson J $200,00
  4. 2022 – 2022 Angiodynamics (USA). IRE Immuno study Extension $100,000
  5. 2022 St. Vincent’s Curran Foundation (Endowment Grant). PIAS study $50,000


Over 180 peer-reviewed publications

Top 5 Recent Invited Conference Presentations

  1. USANZ 2017 – Focal therapy nanoknife and PSMA Imaging and MRI Imaging workshop
  2. Robotic Symposium – Potency preservation in Robotics
  3. PROSCA Portugal – Focal Nanoknife, Robotic RP
  4. Tasmania ASM – Prostate Cancer Update – 8hours
  5. MRI Fusion Workshop – Co Convenor

Other track record achievements in the past 5 years

  • Supervision and mentoring of eight research fellows to Masters or PhD including The Rob Sutherland Fellow
  • Production of patient oriented DVDs for prostate cancer care
  • Invited speaker to twenty national and international conferences and meetings
  • Member of The Expert Advisory Panel to develop books on 1.Treatment of Localised Prostate Cancer –both editions (NHMRC approved )2. Treatment of Advanced Prostate Cancer ( NHMRC Approved ) 3. Clinical Practice guidelines for PSA Testing (PCFA & NHMRC approved )
  • Supervisor of Robotic Surgical Training for Registrars, Fellows and Consultants
  • Reviewer of Publications for multiple Journals including European Urology, Journal of Urology, Medical Journal of Australia.